Intercell acquires antibody technology platform from Cytos
Vienna – Austrian Intercell AG expands its current vaccine business to anti-infective monoclonal antibodies. In a EUR 15 million deal Intercell has bought Cytos' antibody discovery platform technology, the firm announced on 6th May. The technology is based on expression cloning of monoclonal antibodies from human B-cells and enables the identification of anti-infective antibodies to prevent and treat infectious diseases. Under the terms of the agreement Intercell will own certain unpartnered monoclonal antibody assets, including promising pre-clinical anti-infective antibody candidates discovered by Cytos. Key scientists, who have very successfully developed the technology at Cytos, will be employed by Intercell. The antibody technology complements Intercell' technology platforms and opens novel medically and commercially relevant applications for Intercell's Antigen Identification Program (AIP). In its future antibody discovery activities Intercell will focus on medically and commercially attractive AIP derived disease targets including Group B Streptococcus and bacteria involved in hospital acquired infections.